Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jul 7;7(3):69.

Genetic barriers to resistance and impact on clinical response

Andrew D Luber  1
Affiliations
Review

Genetic barriers to resistance and impact on clinical response

Andrew D Luber. MedGenMed. .

Abstract

The development of drug resistance and cross-resistance continues to pose a challenge to successful long-term antiretroviral therapy despite the availability of new antiretroviral agents. The genetic barrier to resistance of a regimen does not directly correlate with its effectiveness. For some regimens with a low genetic barrier to resistance, however, the emergence of only 1 or 2 key resistance mutations may confer drug resistance not only to that regimen but also to other agents, thereby limiting subsequent treatment options. In addition to the genetic barrier to resistance, factors such as efficacy, safety, tolerability, convenience, and adherence must be considered when choosing a regimen.

PubMed Disclaimer

Figures

Figure
Figure
Patients on the TDF + 3TC + ABC regimen in the ESS30009 study demonstrated a high rate of early virologic nonresponse compared with those treated with EFV + 3TC + ABC. Reproduced with permission from Joel E. Gallant, MD.
See this image and copyright information in PMC

References

    1. Hsu RK, Wainberg MA. Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing. J Acquir Immune Defic Syndr. 2004;35(suppl 1):S13–S21.
    1. Kempf D, King M, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51–60. - PubMed
    1. Eron JJ., Jr The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996;10(suppl 5):S11–S19. - PubMed
    1. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4–8, 2001; Chicago, Illinois. Abstract 448.
    1. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 43.

MeSH terms

Substances

LinkOut - more resources